***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: AIMS We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds ( BVS ) for the treatment of patients presenting with ST-segment elevation myocardial infa rct ion ( STEMI ) . METHODS AND RESULTS The present investigation is a prospect i ve , single-arm , single-centre study , reporting data after the  BVS implantation in STEMI patients . Quantitative coronary angiography and optical coherence tomography ( OCT ) data were evaluated . Clinical outcomes are reported at the 30-day follow-up . The intent-to-treat population comprises a total of 49 patients . The procedural success was 97.9 % . Pre-procedure TIMI-flow was 0 in 50.0 % of the patients ; after the BVS implantation , a TIMI-flow III was achieved in 91.7 % of patients and the post-procedure percentage diameter stenosis was 14.7 ± 8.2 % . No patients had angiographically visible residual thrombus at the end of the procedure . Optical coherence tomography analysis performed in 31 patients showed that the post-procedure mean lumen area was 8.02 ± 1.92 mm(2 ) , minimum lumen area 5.95 ± 1.61 mm(2 ) , mean incomplete scaffold apposition area 0.118 ± 0.162 mm(2 ) , mean intraluminal defect area 0.013 ± 0.017 mm(2 ) , and mean percentage malapposed struts per patient 2.80 ± 3.90 % . Scaffolds with > 5 % malapposed struts were 7 . At the 30-day follow-up , target-lesion failure rate was 0 % . Non-target-vessel revascularization and target-vessel myocardial infa rct ion ( MI ) were reported . A non-target-vessel non-Q-wave MI occurred . No cases of cardiac death or scaffold thrombosis were observed . CONCLUSION In the present series , the BVS implantation  in patients presenting with acute MI appeared feasible , with high rate of final TIMI-flow III and good scaffold apposition . Larger studies are currently needed to confirm these preliminary data Objective of this study was to assess the clinical performance of bioresorbable vascular scaffold ( BVS ) compared to everolimus-eluting stent ( EES ) in subjects with ST-segment elevation myocardial infa rct ion ( STEMI ) . We included all consecutive patients with STEMI who underwent percutaneous coronary intervention ( PCI ) with BVS implantation in centers participating to the Italian ABSORB Prospect i ve Registry ( BVS-RAI ) and PCI with EES in the same centers during the same period . The 2 groups were compared . The primary end point was patient-oriented composite end point ( POCE ) including cardiac death , myocardial infa rct ion , and target lesion revascularization ( TLR ) at the longest available follow-up . BVS or EES thrombosis at follow-up was also evaluated . Of the 563 patients with STEMI included , 122 received BVS and 441 EES .  Procedural success was obtained in 549 ( 97.5 % ) cases without significant differences between the 2 groups ( BVS 99.3 % vs EES 97.0 % , p = 0.2 ) . At a median of 220-day ( interquartile range 178 to 369 ) follow-up , no significant differences were observed in terms of POCE ( BVS 4.9 % vs EES 7.0 % , p = 0.4 ) ; death ( BVS 0.8 % , EES 2.0 % , p = 0.4 ) , MI ( BVS 4.1 % , EES 2.0 % , p = 0.2 ) , TLR ( BVS 4.1 % , EES 4.5 % , p = 0.8 ) , device thrombosis ( BVS 2.5 % , EES 1.4 % , p = 0.4 ) . All TLR cases were successfully managed with re-PCI in both groups . A propensity matching of the study population s showed no significant differences regarding POCE at the longest available follow-up ( odds ratio 0.53 , 0.1 to 4.3 ) . In conclusion , in this direct prospect i ve comparison , BVS was associated with similar clinical results compared to EES in the STEMI setting . Larger and adequately powered r and omized trials are needed to fully assess the potential clinical benefit of BVS versus the current st and ard of care in patients with STEMI BACKGROUND In patients with coronary artery disease who receive metallic drug-eluting coronary stents , adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall . Bioresorbable vascular scaffolds have been developed to attempt to improve long-term outcomes . METHODS In this large , multicenter , r and omized trial , 2008 patients with stable or unstable angina were r and omly assigned in a 2:1 ratio to receive an everolimus-eluting bioresorbable vascular ( Absorb ) scaffold ( 1322 patients ) or an everolimus-eluting cobalt-chromium ( Xience ) stent ( 686 patients ) . The primary end point , which was tested for both noninferiority ( margin , 4.5 percentage points for the risk difference ) and superiority , was target-lesion failure ( cardiac death , target-vessel myocardial infa rct ion , or ischemia-driven target-lesion revascularization ) at 1 year . RESULTS Target-lesion failure at 1 year occurred in 7.8 % of patients in the Absorb group and in 6.1 % of patients in the Xience group ( difference , 1.7 percentage points ; 95 % confidence interval , -0.5 to 3.9 ; P=0.007 for noninferiority and P=0.16 for superiority ) . There was no significant difference between the Absorb group and the Xience group in rates of cardiac death ( 0.6 % and 0.1 % , respectively ; P=0.29 ) , target-vessel myocardial infa rct ion ( 6.0 % and 4.6 % , respectively ; P=0.18 ) , or ischemia-driven target-lesion revascularization ( 3.0 % and 2.5 % , respectively ; P=0.50 ) . Device thrombosis within 1 year occurred in 1.5 % of patients in the Absorb group and in 0.7 % of patients in the Xience group ( P=0.13 ) . CONCLUSIONS In this large-scale , r and omized trial , treatment of noncomplex obstructive coronary artery disease with an everolimus-eluting bioresorbable vascular scaffold , as compared with an everolimus-eluting cobalt-chromium stent , was within the prespecified margin for noninferiority with respect to target-lesion failure at 1 year . ( Funded by Abbott Vascular ; ABSORB III Clinical Trials.gov number , NCT01751906 . ) BACKGROUND The first CE-approved bioresorbable vascular scaffold ( BVS ) is effective at treating simple lesions and stable coronary artery disease , but it has yet to be assessed versus the best-in-class drug-eluting stents ( DES ) . OBJECTIVES This study sought to compare the performance of a BVS with that of everolimus-eluting stents ( EES ) and biolimus-eluting stents ( BES ) in all-comer patients . METHODS The EVERBIO II ( Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents II ) trial was a single-center , assessor-blinded study of 240 patients r and omly assigned in a 1:1:1 ratio to EES , BES , or BVS .  The only exclusion criterion was a reference vessel diameter > 4.0 mm , which precluded treatment with BVS . The primary endpoint was angiographic late lumen loss ( LLL ) at 9 months . Secondary endpoints included patient-oriented major acute coronary events ( MACE ) ( death , myocardial infa rct ion [ MI ] , and any revascularization ) , device-oriented MACE ( cardiac death , MI , and target lesion revascularization ) , and stent thrombosis at the 9-month clinical follow-up . RESULTS Follow-up angiography was performed in 216 patients ( 90.7 % ) at 9 months . In-stent LLL was similar between patients treated with BVS ( 0.28 ± 0.39 mm ) and those treated with EES/BES ( 0.25 ± 0.36 mm ; p = 0.30 ) . Clinical outcomes were similar at 9 months : the patient-oriented MACE rate was 27 % in BVS and 26 % in the EES/BES group ( p = 0.83 ) and the device-oriented MACE rate was 12 % in BVS and 9 % in the EES/BES group ( p = 0.6 ) . CONCLUSIONS New-generation metallic DES ( EES/BES ) were not superior to BVS in terms of angiographic LLL and clinical outcomes . ( Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents [ EVERBIO II ] ; NCT01711931 ) OBJECTIVES This study sought to perform clinical and imaging assessment s of the DESolve Bioresorbable Coronary Scaffold ( BCS ) . BACKGROUND BCS , which is drug eluting , may have potential advantages compared with conventional metallic drug-eluting stents . The DESolve system , design ed to provide vessel support and neointimal suppression , combines a poly-l-lactic acid-based scaffold with the antiproliferative myolimus . METHODS The DESolve First-in-Man ( a non-r and omized , consecutive enrollment evaluation of the DESolve myolimus eluting bioresorbable coronary stent in the treatment of patients with de novo native coronary artery lesions ) trial was a prospect i ve multicenter study enrolling 16 patients eligible for treatment . The principal safety endpoint was a composite of cardiac death , myocardial infa rct ion , and clinical ly indicated target lesion revascularization . The principal imaging endpoint was in-scaffold late lumen loss ( LLL ) assessed by quantitative coronary angiography ( QCA ) at 6 months . Intravascular ultrasound ( IVUS ) and optical coherence tomography ( OCT ) imaging was performed at baseline and 6 months ; multislice computed tomography ( MSCT ) was performed at 12 months . RESULTS Acute procedural success was achieved in 15 of 15 patients receiving a study scaffold . At 12 months , there was no scaffold thrombosis and no major adverse cardiac events directly attributable to the scaffold . At 6 months , in-scaffold LLL ( by QCA ) was 0.19 ± 0.19 mm ; neointimal volume ( by IVUS ) was 7.19 ± 3.56 % , with no evidence of scaffold recoil or late malapposition . Findings were confirmed with OCT and showed uniform , thin neointimal coverage ( 0.12 ± 0.04 mm ) . At 12 months , MSCT demonstrated excellent vessel patency . CONCLUSIONS This study demonstrated the feasibility and efficacy of the DESolve BCS . Results showing low in-scaffold LLL , low % neointimal volume at 6 months , no chronic recoil , and maintenance of lumen patency at 12 months prompt further study . ( DESolve First-in-Man ; EudraCT number 2011 - 000027 - 32 ) 
    Output:
    
Our meta- analysis suggests a significantly higher risk of TVMI with BRS compared with conventional stents and no significant differences in the rates of occurrence of the other outcomes during one-year follow-up .